Scholarlink

<p>This study evaluated the bioactivity of pomegranate peel, particularly after simulated gastrointestinal digestion, in an in-vitro Alzheimer’s disease model. Human glioblastoma U87MG cells exposed to Aβ<sub>1−42</sub> were used to assess the effects of both digested and non-digested pomegranate peel on Aβ aggregation and inflammatory responses. In-vitro digestion simulated oral, gastric, and intestinal phases, and polyphenol profiles were analyzed before and after digestion. Cytotoxicity was examined using MTT assays, Aβ disaggregation by ELISA, and fibril morphology by field emission scanning electron microscopy (FESEM). Anti-inflammatory activity was evaluated via qRT-PCR in LPS-stimulated Raw264.7 macrophages, focusing on iNOS, IL-6, TNF-α, NF-κB, COX-2, and IL-10 expression. Despite partial degradation during digestion, both forms of peel retained bioactivity. At non-toxic concentrations, they supported cell viability and reduced Aβ aggregation (57.21% for non-digested, 42.11% for digested peel). FESEM confirmed fibril disruption, and both forms downregulated pro-inflammatory genes while enhancing IL-10 expression. These findings suggest that pomegranate peel, even after digestion, preserves anti-amyloidogenic and immunomodulatory activities in-vitro, supporting its potential as a dietary ingredient that merits further investigation in the context of Alzheimer’s disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An investigation on amyloid beta plaque dissociation in U87MG cells of in-vitro digested pomegranate peel

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月16日

查看全文
  • Ünkan Urganci,
  • Fatma Isik,
  • Sevki Arslan

摘要

This study evaluated the bioactivity of pomegranate peel, particularly after simulated gastrointestinal digestion, in an in-vitro Alzheimer’s disease model. Human glioblastoma U87MG cells exposed to Aβ1−42 were used to assess the effects of both digested and non-digested pomegranate peel on Aβ aggregation and inflammatory responses. In-vitro digestion simulated oral, gastric, and intestinal phases, and polyphenol profiles were analyzed before and after digestion. Cytotoxicity was examined using MTT assays, Aβ disaggregation by ELISA, and fibril morphology by field emission scanning electron microscopy (FESEM). Anti-inflammatory activity was evaluated via qRT-PCR in LPS-stimulated Raw264.7 macrophages, focusing on iNOS, IL-6, TNF-α, NF-κB, COX-2, and IL-10 expression. Despite partial degradation during digestion, both forms of peel retained bioactivity. At non-toxic concentrations, they supported cell viability and reduced Aβ aggregation (57.21% for non-digested, 42.11% for digested peel). FESEM confirmed fibril disruption, and both forms downregulated pro-inflammatory genes while enhancing IL-10 expression. These findings suggest that pomegranate peel, even after digestion, preserves anti-amyloidogenic and immunomodulatory activities in-vitro, supporting its potential as a dietary ingredient that merits further investigation in the context of Alzheimer’s disease.